Supply of Chloromycetin Eye Ointment by Pfizer Australia

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the importation, supply, and advertising of therapeutic goods in Australia. It was introduced to address the need for a comprehensive legal framework to ensure the safety, efficacy, and quality of therapeutic goods available to the public. The Act provides the necessary legislative foundation for the Therapeutic Goods Administration (TGA) to monitor and control therapeutic goods, thereby safeguarding public health. The 1989 Act was enacted by the Parliament of Australia, reflecting the policy objective of maintaining and improving the health of Australians through stringent regulation of therapeutic goods. This specific notice, issued by Mayada Kayali, the Delegate of the Secretary to the Department of Health, pertains to an exemption granted under sections 14 and 14A of the Therapeutic Goods Act 1989. The exemption allows Pfizer Australia Pty Ltd to supply Chloromycetin eye ointment, which does not fully comply with the labelling requirements stipulated in the Therapeutic Goods Order No. 69. This consent is conditional, ensuring that the medicine adheres to all other regulatory standards and is limited to specific batches. The exemption is issued to facilitate the supply of the medicine while addressing a minor non-compliance issue, thereby balancing regulatory compliance with public health needs.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration within the Commonwealth of Australia, pertains to the regulation of therapeutic goods, including medicines, medical devices, and other health-related products. Section 14 and 14A of the Act allow for the issuance of consents that permit deviations from specified standards under certain conditions, facilitating the supply of therapeutic goods that would otherwise not fully comply with certain regulatory requirements. This particular consent applies to Pfizer Australia Pty Ltd, permitting the supply of CHLOROMYCETIN eye ointment, specifically for the batches identified, which does not comply with the requirement for the batch number prefix on the tube label. This exemption is limited to the specified batches and is subject to the condition that all other aspects of the standard are met. The scope of this Act extends across the Commonwealth, ensuring that therapeutic goods supplied in Australia meet the necessary safety, quality, and efficacy standards. The Act's application is comprehensive, covering all entities involved in the supply of therapeutic goods, including manufacturers, importers, and distributors, ensuring a uniform standard of health and safety across the nation.

Key Provisions

Section 14 of the Therapeutic Goods Act 1989 allows the Delegate of the Secretary to the Department of Health to give consent for the supply of therapeutic goods that do not comply with certain standards or specifications. This specific notice, issued to Pfizer Australia Pty Ltd, pertains to the supply of CHLOROMYCETIN eye ointment. Under section 14A, the Delegate has permitted the supply of this medicine despite it not meeting a particular requirement of the Therapeutic Goods Order No. 69 – General requirements for medicine labels, specifically concerning the batch number prefix on the tube label. The obligations imposed by this Act on Pfizer Australia Pty Ltd include ensuring that the medicine complies with all other aspects of the standard, as stated in the notice. They must also ensure that the exemption only applies to the specified batches of the medicine, which are Batch 073081 and Batch 073082, both with an expiry date of July 2016. This means that Pfizer Australia Pty Ltd must carefully manage the distribution and use of these specific batches to comply with the conditions set out in the notice. Breaching the conditions outlined in the notice can have legal consequences. Although the specific Act does not outline penalties, under general principles of Australian law, non-compliance with conditions set by a governmental delegate can lead to legal action. This could include civil penalties or even criminal charges in more severe cases of non-compliance. The exact penalties would depend on the nature and severity of the breach but could potentially include fines or other corrective actions mandated by a court. It is crucial for Pfizer Australia Pty Ltd to adhere strictly to the conditions to avoid any adverse legal outcomes.